Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge.

ABSTRACT: Modified Vaccinia Ankara (MVA) was recently approved as a smallpox vaccine. Variola is transmitted by respiratory droplets and MVA immunization by skin scarification (s.s.) protected mice far more effectively against lethal respiratory challenge with vaccinia virus (VACV) than any other route of delivery, and at lower doses. Comparisons of s.s. with intradermal, subcutaneous, or intramuscular routes showed that MVA_OVA s.s.-generated T cells were both more abundant and transcriptionally unique. MVA_OVA s.s. produced greater numbers of lung Ova-specific CD8⁺ T_RM and was superior in protecting mice against lethal VACV_OVA respiratory challenge. Nearly as many lung T_RM were generated with MVA_OVA s.s. immunization compar

SUBMITTER: Pan Y 

PROVIDER: S-EPMC7782760 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature